



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

JPL/SEC/LODR-Comp/results-Not1

Date : February 9th, 2018

The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandara-Kurla Complex
Bandra (E), Mumbai - 400 051.
Ph. 022-26598452

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Tower
Dalal Street,
Mumbai - 400 001
Ph. 022-22721234

**SUB: UN-AUDITED STANDALONE FINANCIAL RESULTS FOR QUARTER ENDED
31.12.2017 & LIMITED REVIEW.**

Dear Sir,

Please find enclosed herewith un-audited financial results along with Limited Review for the quarter / nine months ended 31st December, 2017.

Thanking you.

Yours faithfully,

JAGSONPAL PHARMACEUTICALS LIMITED



R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

CIN No.- L74899DL1978PLC009181

Statement of Standalone Unaudited Financial Results for the Quarter ended 31.12.2017 and Nine Month Ended 31.12.2017
Rs. in lacs

Particulars	Standalone					12 Months Ended 31.03.2017 Audited
	Quarter Ended		Nine Month Ended		31.03.2017	
	31.12.2017	30.09.2017	31.12.2016	31.12.2017		
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1 Income from operations						
a Gross Sales/Revenue from Operations	3605.05	2890.00	3440.34	9393.11	11476.32	14007.20
b Other Operating Income	0.00	0.00	0.00	0.00	27.17	39.04
Total Income from operations	3605.05	2890.00	3440.34	9393.11	11503.49	14046.24
2 Other Income	3.06	17.21	0.03	32.42	0.32	7.84
3 Total Income I 1+2	3608.11	2907.21	3440.37	9425.53	11503.81	14054.08
4 Expenses						
a Cost of materials consumed	954.56	1636.19	1493.56	4350.88	4256.62	5357.47
b Purchases of stock-in-trade	596.82	61.38	251.98	1063.62	819.11	1046.42
c Changes in inventories of finished goods, work in progress and stock-in-trade	479.49	-146.34	-9.63	-493.39	-145.89	-438.92
d Excise Duty	0.00	0.00	8.10	7.15	25.16	120.16
e Employee benefits expenses	1042.54	1104.97	967.87	3105.77	3055.42	4053.20
f Finance Cost	22.66	19.16	56.12	60.44	241.06	264.48
g Depreciation and amortisation expense	2.11	1.89	33.29	26.47	176.52	199.40
h Other expenses	940.28	523.12	659.11	2283.43	2789.29	3620.02
Total expenses	4637.97	3302.58	3435.33	10487.35	11353.49	14594.23
5 Profit before exceptional items and taxes (3-4)	-229.26	-394.47	7.02	-1061.80	150.12	158.85
6 Exceptional items	0.00	0.00	1279.81	0.00	1279.81	1279.81
7 Profit before tax (5+6)	-229.26	-394.47	1286.83	-1061.80	1429.93	1429.93
8 Tax expense	-1.56	-9.13	236.41	-13.69	325.04	253.20
9 Net Profit for the period (7-8)	-224.70	-385.34	990.42	-1028.11	1104.89	1186.66
10 Other Comprehensive Income						
a (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
11 Total Other Comprehensive Income (Aii) - All(0)	0.00	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income (9+11)	-224.70	-385.34	990.42	-1028.11	1104.89	1186.66
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1300.00	1300.00	1300.00	1300.00	1300.00	1300.00
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)						
a. Basic (Rs.)	-0.86	-1.47	3.78	-3.92	4.22	4.53
b. Diluted (Rs.)	-0.86	-1.47	3.78	-3.92	4.22	4.53

Notes

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 9, 2018.
- In line with the provisions of Ind AS 108, the Company operates in one reportable business segment i.e. Pharmaceuticals.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder. The date of transition to Ind AS is April 1, 2016. The impact of transition if any has been accounted for in the opening reserves and the comparative period results have been restated accordingly. The opening balance sheet as at April 1, 2016 and the results for the subsequent periods would be finalized and will be subject to audit at the time of annual financial statements for the year ended March 31, 2018.
- According to the requirements of Ind AS and SCDD (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding previous quarter ended June 30, 2017 and December 31, 2016 for the nine months ended December 31, 2016, were reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("GST") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. AS per Ind AS 18, the revenue for the quarter ended December 31, 2017, is reported net of GST and is not comparable with previous reported quarter.
- Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under Ind AS are given below:

Particulars	Quarter ended 31.12.2016	Year to date ended 31.12.2016
Net Profit for the period as per Indian GAAP		
Adjustments:	990.42	1104.89
Net Profit for the period as per Ind AS	990.42	1104.89
Total Comprehensive Income as per Ind AS	990.42	1104.89



Place : New Delhi
Date : 09-02-2018



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
CIN No 00009492



The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

1. We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter ended December 31, 2017 which are included in the accompanying Statement of Standalone Financial Results for the Quarter ended December 31, 2017 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initiated by us for identification purposes. The Statement is the responsibility of the Company's management and is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the Preparation of the Company's opening unaudited Balance Sheet as at April 1, 2016 prepared in accordance with the Companies (Indian Accounting Standards) rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matters:
 - a. Note to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017 and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.
 - b. We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter and nine months ended December 31, 2016 and the previous year ended December 31, 2016 accordingly, we do not express any conclusion on the results in the Statement for the quarter and nine months ended September 30, 2016 and previous year ended December 31, 2016, respectively. These figures have been furnished by the Management.




- c. The standalone financial statements of the Company for the year ended March 31, 2016 prepared in accordance with Companies (Accounting Standards) Rules, 2006, were audited by another firm of chartered accountants under the Companies Act, 2013 who, vide their report dated March 28, 2017, expressed an unmodified opinion on those financial statements. Accordingly, the net profit included in the reconciliation to the Company's Total Comprehensive Income for the quarter ended on December 31, 2016 is based on such financial statements.

Our conclusion is not qualified in respect of these matters.

New Delhi
09. 02. 2018

For H.L. Bansal & Co.
Firm Registration Number 008563N
Chartered Accountants



H. L. Bansal

H. L. Bansal
Proprietor
Membership Number 086990



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

JPL/Stock-Corr-2013	February 9th, 2018
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager Listing Agreement The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote : JAGSNPHARM	Scrip Code : 507789
OUT-COME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON 09.02.2018	

Sir,

- Performance of the 3rd Quarter and three/nine months unaudited Financial Results ended 31.12.2017 was placed before the Board, having been reviewed by the Audit Committee. The issue was discussed.
- Approval of Quarterly performance and three/nine months ended 31.12.2017 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks.
- The meetings commence at 11.00 a.m noon and concluded at 2.15 p.m.

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACEUTICALS LIMITED



R K KAPOOR
COMPLIANCE OFFICER & COMPANY SECRETARY

- CMA Subhasis Patri was appointed as Cost Auditor of the Company due to vacancy created due to death of Sh. S. N. Balasubramanian, Cost Auditor.